Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
40433 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A00001 | 35259705 | Diabetes Metab Syndr | Role of diabetologists in the management of nonalcoholic fatty liver disease: Primary prevention and screening/management of fibrosis and cirrhosis. | 2022 | Details |
| A00002 | 35259493 | Cell Mol Gastroenterol Hepatol | Coordinated Cross-Talk Between the Myc and Mlx Networks in Liver Regeneration and Neoplasia. | 2022 | Details |
| A00003 | 35259337 | Chem Phys Lipids | New insights into NAFLD based on preclinical MRI studies. | 2022 | Details |
| A00004 | 35258780 | Chin J Integr Med | Protective Roles of Shilajit in Modulating Resistin, Adiponectin, and Cytokines in Rats with Non-alcoholic Fatty Liver Disease. | 2022 | Details |
| A00005 | 35258483 | Endocr Connect | Menopause-associated risk of cardiovascular disease. | 2022 | Details |
| A00006 | 35256934 | Acta Pharm Sin B | Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma. | 2021 | Details |
| A00007 | 35256601 | Cell Death Discov | LncRNA MEG3 up-regulates SIRT6 by ubiquitinating EZH2 and alleviates nonalcoholic fatty liver disease. | 2022 | Details |
| A00008 | 35256204 | Transplant Proc | Visceral Fat Area Is an Independent Risk Factor for Overweight or Obese Nonalcoholic Fatty Liver Disease in Potential Living Liver Donors. | 2022 | Details |
| A00009 | 35256195 | Thromb Res | Impaired fibrinolysis without hypercoagulability characterises patients with non-alcoholic fatty liver disease. | 2022 | Details |
| A00010 | 35255811 | BMC Gastroenterol | The effect of daily consumption of probiotic yogurt on liver enzymes, steatosis and fibrosis in patients with nonalcoholic fatty liver disease (NAFLD): study protocol for a randomized clinical trial. | 2022 | Details |
| A00011 | 35255600 | Endocrinol Metab (Seoul) | State-of-the-Art Overview of the Pharmacological Treatment of Non-Alcoholic Steatohepatitis. | 2022 | Details |
| A00012 | 35255597 | Endocrinol Metab (Seoul) | The Influence of Obesity and Metabolic Health on Vascular Health. | 2022 | Details |
| A00013 | 35255263 | Lancet Oncol | Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis. | 2022 | Details |
| A00014 | 35254877 | Arch Physiol Biochem | Resveratrol attenuates against high-fat-diet-promoted non-alcoholic fatty liver disease in rats mainly by targeting the miR-34a/SIRT1 axis. | 2022 | Details |
| A00015 | 35254642 | Hepatol Int | MRE-based NASH score for diagnosis of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease. | 2022 | Details |
| A00016 | 35252828 | JHEP Rep | Macrophage MerTK promotes profibrogenic cross-talk with hepatic stellate cells via soluble mediators. | 2022 | Details |
| A00017 | 35252807 | iScience | A network-based computational and experimental framework for repurposing compounds toward the treatment of non-alcoholic fatty liver disease. | 2022 | Details |
| A00018 | 35252260 | Front Med (Lausanne) | Intermittent Hypoxia Rewires the Liver Transcriptome and Fires up Fatty Acids Usage for Mitochondrial Respiration. | 2022 | Details |
| A00019 | 35252196 | Front Cell Dev Biol | ULK1 Signaling in the Liver: Autophagy Dependent and Independent Actions. | 2022 | Details |
| A00020 | 35251901 | Australas J Ultrasound Med | Portal Venous Pulsatility Index as a predictor of fibrosis in patients with non-alcoholic fatty liver disease. | 2021 | Details |
| A00021 | 35251583 | J Healthc Eng | Preliminary Study on Risk Factors for Morbidity of Nonalcoholic Fatty Liver Disease in High-Income Male Population. | 2022 | Details |
| A00022 | 35251469 | Oxid Med Cell Longev | Farnesoid X Receptor Deficiency Induces Hepatic Lipid and Glucose Metabolism Disorder via Regulation of Pyruvate Dehydrogenase Kinase 4. | 2022 | Details |
| A00023 | 35251371 | Dis Markers | Dose-Response Associations of Metabolic Score for Insulin Resistance Index with Nonalcoholic Fatty Liver Disease among a Nonobese Chinese Population: Retrospective Evidence from a Population-Based Cohort Study. | 2022 | Details |
| A00024 | 35251356 | EFSA J | Tolerable upper intake level for dietary sugars. | 2022 | Details |
| A00025 | 35251100 | Front Plant Sci | Raffinose Family Oligosaccharides: Friend or Foe for Human and Plant Health? | 2022 | Details |
| A00026 | 35251036 | Front Immunol | Bidirectional Association Between Psoriasis and Nonalcoholic Fatty Liver Disease: Real-World Evidence From Two Longitudinal Cohort Studies. | 2022 | Details |
| A00027 | 35250889 | Front Endocrinol (Lausanne) | Corrigendum: Pioglitazone for NAFLD Patients With Prediabetes or Type 2 Diabetes Mellitus: A Meta-Analysis. | 2022 | Details |
| A00028 | 35250880 | Front Endocrinol (Lausanne) | A Bidirectional Relationship Between Hyperuricemia and Metabolic Dysfunction-Associated Fatty Liver Disease. | 2022 | Details |
| A00029 | 35250856 | Front Endocrinol (Lausanne) | Not Enough Fat: Mouse Models of Inherited Lipodystrophy. | 2022 | Details |
| A00030 | 35250593 | Front Pharmacol | Combined Use of Bicyclol and Berberine Alleviates Mouse Nonalcoholic Fatty Liver Disease. | 2022 | Details |
| A00031 | 35250588 | Front Pharmacol | Platelets in Non-alcoholic Fatty Liver Disease. | 2022 | Details |
| A00032 | 35250014 | Ultrasound Q | Clinical Feasibility of Shear Wave Dispersion Slope for Noninvasive Diagnosis of Nonalcoholic Steatohepatitis in Patients With Morbid Obesity: Preliminary Results Using US Shear Wave Elastography. | 2022 | Details |
| A00034 | 35249505 | Curr Drug Saf | Pioglitazone, Bladder Cancer and the Presumption of Innocence. | 2022 | Details |
| A00035 | 35249343 | Ann Palliat Med | Serum level of free thyroxine is an independent risk factor for non-alcoholic fatty liver disease in euthyroid people. | 2022 | Details |
| A00036 | 35249342 | Ann Palliat Med | Risk factors and correlation of colorectal polyps with type 2 diabetes mellitus. | 2022 | Details |
| A00037 | 35248654 | Diabetes Res Clin Pract | Metabolic determinants of NAFLD in adults with type 1 diabetes. | 2022 | Details |
| A00038 | 35248539 | Gastroenterology | NAFLD and the Gut-Liver Axis: Exploring an Undernutrition Perspective. | 2022 | Details |
| A00039 | 35247883 | Cancer Epidemiol Biomarkers Prev | Cancer epidemiology in Hispanic populations: what have we learned and where do we need to make progress? | 2022 | Details |
| A00040 | 35247631 | Cell Mol Gastroenterol Hepatol | The critical and diverse roles of CD4-CD8- double negative T cells in nonalcoholic fatty liver disease. | 2022 | Details |
| A00041 | 35247611 | Mol Metab | Serum Amyloid A1 Exacerbates Hepatic Steatosis via TLR4 Mediated NF-κB Signaling Pathway. | 2022 | Details |
| A00044 | 35246007 | Bioengineered | Quantitative proteomics analysis based on tandem mass tag labeling coupled with labeling coupled with liquid chromatography-tandem mass spectrometry discovers the effect of silibinin on non-alcoholic fatty liver disease in mice. | 2022 | Details |
| A00045 | 35245436 | Mol Cell | Amelioration of hepatic steatosis by dietary essential amino acid-induced ubiquitination. | 2022 | Details |
| A00046 | 35244697 | J Clin Endocrinol Metab | Visit-to-Visit Fasting Glucose Variability in Young Adulthood and Non-Alcoholic Fatty Liver Disease in Middle Age. | 2022 | Details |
| A00047 | 35244676 | Am J Clin Nutr | Sex-related association of NAFLD and liver fibrosis with body fat distribution in the general US population. | 2022 | Details |
| A00048 | 35243281 | JHEP Rep | Artificial intelligence in liver diseases: Improving diagnostics, prognostics and response prediction. | 2022 | Details |
| A00049 | 35243280 | JHEP Rep | Cellular origins of regenerating liver and hepatocellular carcinoma. | 2021 | Details |
| A00050 | 35243111 | Transl Gastroenterol Hepatol | Palm tocotrienol rich fraction with palm kernel oil supplementation prevents development of liver steatosis in high fat diet ICR mice. | 2022 | Details |
| A00051 | 35242578 | Mol Genet Metab Rep | Expression signature of the Leigh syndrome French-Canadian type. | 2022 | Details |
| A00052 | 35242173 | PPAR Res | Role of Apolipoprotein A1 in PPAR Signaling Pathway for Nonalcoholic Fatty Liver Disease. | 2022 | Details |
| A00053 | 35242045 | Front Physiol | Feasibility, Efficacy, and Safety of Percutaneous Muscle Biopsies in Patients With Chronic Liver Disease. | 2022 | Details |
| A00054 | 35241921 | J Inflamm Res | Reduction of Hepatic Steatosis, Oxidative Stress, Inflammation, Ballooning and Insulin Resistance After Therapy with Safranal in NAFLD Animal Model: A New Approach. | 2022 | Details |
| A00055 | 35240510 | Biochem Biophys Res Commun | Inulin activates FXR-FGF15 signaling and further increases bile acids excretion in non-alcoholic fatty liver disease mice. | 2022 | Details |
| A00056 | 35240344 | Cell Mol Gastroenterol Hepatol | Activation of Liver mTORC1 Protects Against NASH via Dual Regulation of VLDL-TAG Secretion and De Novo Lipogenesis. | 2022 | Details |
| A00057 | 35238939 | J Clin Endocrinol Metab | Long or Irregular Menstrual Cycles and Risk of Prevalent and Incident Nonalcoholic Fatty Liver Disease. | 2022 | Details |
| A00058 | 35238782 | Turk J Gastroenterol | Evaluation of Magnetic Resonance Elastography and Transient Elastography for Liver Fibrosis and Steatosis Assessments in the Liver Transplant Setting. | 2022 | Details |
| A00059 | 35238641 | Proc Natl Acad Sci U S A | Disruption of the circadian clock component BMAL1 elicits an endocrine adaption impacting on insulin sensitivity and liver disease. | 2022 | Details |
| A00060 | 35237077 | Hepat Med | Evaluation of the Effect of Hydromethanolic Seed Extract of Lepidium sativum L. (Fetto) on Deep-fried Palm Oil Diet Induced Nonalcoholic Fatty Liver Disease on Male Swiss Albino Mice. | 2022 | Details |
| A00061 | 35236351 | Lipids Health Dis | Circulating chemerin levels in metabolic-associated fatty liver disease: a systematic review and meta-analysis. | 2022 | Details |
| A00062 | 35235789 | Cell Rep | Distinct hepatic immunological patterns are associated with the progression or inhibition of hepatocellular carcinoma. | 2022 | Details |
| A00063 | 35235219 | Aliment Pharmacol Ther | Review article: current and emerging therapies for the management of cirrhosis and its complications. | 2022 | Details |
| A00064 | 35234251 | Clin Sci (Lond) | MicroRNAs as messengers of liver diseases: has the message finally been decrypted? | 2022 | Details |
| A00065 | 35233386 | J Clin Transl Hepatol | Influence of Nonalcoholic Fatty Liver Disease on the Occurrence and Severity of Chronic Kidney Disease. | 2021 | Details |
| A00066 | 35233381 | J Clin Transl Hepatol | Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) and Viral Hepatitis. | 2021 | Details |
| A00067 | 35233368 | J Clin Transl Hepatol | Comparing the Diagnostic Criteria of MAFLD and NAFLD in the Chinese Population: A Population-based Prospective Cohort Study. | 2021 | Details |
| A00069 | 35232986 | Sci Rep | Liver injury in non-alcoholic fatty liver disease is associated with urea cycle enzyme dysregulation. | 2022 | Details |
| A00070 | 35232007 | Clin Mol Hepatol | NAFLD increases Risk of Carotid Atherosclerosis and Ischemic Stroke. An Updated Meta-Analysis with 135,602 Individuals. | 2022 | Details |
| A00071 | 35231745 | Surg Oncol | Long-term surgical outcomes of Non alcoholic fatty liver disease associated hepatocellular carcinoma. | 2022 | Details |
| A00072 | 35230646 | Neurochem Res | Non-alcoholic Fatty Liver Disease: Also a Disease of the Brain? A Systematic Review of the Preclinical Evidence. | 2022 | Details |
| A00073 | 35230526 | Langenbecks Arch Surg | Is there a role for preoperative liver reducing diet in hepatectomy? A systematic review. | 2022 | Details |
| A00074 | 35230042 | Swiss Med Wkly | Increasing prevalence of obesity and diabetes among patients evaluated for liver transplantation in a Swiss tertiary referral center: a 10-year retrospective analysis. | 2022 | Details |
| A00075 | 35229847 | Food Funct | N-Acetylcysteine alleviates high fat diet-induced hepatic steatosis and liver injury via regulating the intestinal microecology in mice. | 2022 | Details |
| A00076 | 35229334 | Aliment Pharmacol Ther | Comparative efficacy of an optimal exam between ultrasound versus abbreviated MRI for HCC screening in NAFLD cirrhosis: A prospective study. | 2022 | Details |
| A00077 | 35229329 | Hepatology | Risk Factors for Hepatocellular Cancer in Contemporary Cohorts of Patients with Cirrhosis. | 2022 | Details |
| A00078 | 35229183 | Pediatr Radiol | Diagnostic performance of ultrasound hepatorenal index for the diagnosis of hepatic steatosis in children. | 2022 | Details |
| A00079 | 35229049 | Health Sci Rep | Associations between aflatoxin B1-albumin adduct levels with metabolic conditions in Guatemala: A cross-sectional study. | 2022 | Details |
| A00080 | 35227957 | Clin Res Hepatol Gastroenterol | The impact of metabolic health on non-alcoholic fatty liver disease (NAFLD). A single center experience. | 2022 | Details |
| A00081 | 35227956 | Clin Res Hepatol Gastroenterol | Abnormal liver tests and non-alcoholic fatty liver disease predict disease progression and outcome of patients with Covid-19. | 2022 | Details |
| A00082 | 35227772 | Life Sci | sSTEAP4 regulates cellular homeostasis and improves high-fat-diet-caused oxidative stress in hepatocytes. | 2022 | Details |
| A00083 | 35226932 | Ultraschall Med | Point Shear Wave Elastography by ElastPQ for Fibrosis Screening in Patients with NAFLD: A Prospective, Multicenter Comparison to Vibration-Controlled Elastography. | 2022 | Details |
| A00084 | 35226292 | Indian J Gastroenterol | Profile of patients with hepatocellular carcinoma: An experience from a tertiary care center in India. | 2022 | Details |
| A00085 | 35226250 | Cell Biol Toxicol | AS3MT facilitates NLRP3 inflammasome activation by m6A modification during arsenic-induced hepatic insulin resistance. | 2022 | Details |
| A00086 | 35225189 | Br J Nutr | Organ meat consumption and risk of nonalcoholic fatty liver disease: the TCLSIH study. | 2022 | Details |
| A00087 | 35224757 | Histopathology | Utility of sonic hedgehog and keratin 8/18 immunohistochemistry for detecting ballooned hepatocytes. | 2022 | Details |
| A00088 | 35223941 | Front Nutr | Cumulative Betel Quid Chewing and the Risk of Significant Liver Fibrosis in Subjects With and Without Metabolic Syndrome. | 2022 | Details |
| A00089 | 35223701 | Front Pediatr | Association Between Non-invasive Diagnostic Methods of Liver Fibrosis and Type 2 Diabetes in Pediatric Patients With Non-alcoholic Fatty Liver Disease. | 2022 | Details |
| A00090 | 35223680 | Clin Nutr Res | Red and Processed Meat Intake in Relation to Non-Alcoholic Fatty Liver Disease Risk: Results from a Case-Control Study. | 2022 | Details |
| A00091 | 35222903 | Ther Adv Chronic Dis | Nicotinamide supplementation in diabetic nonalcoholic fatty liver disease patients: randomized controlled trial. | 2022 | Details |
| A00092 | 35222799 | Oxid Med Cell Longev | 4-Octyl Itaconate Prevents Free Fatty Acid-Induced Lipid Metabolism Disorder through Activating Nrf2-AMPK Signaling Pathway in Hepatocytes. | 2022 | Details |
| A00093 | 35222075 | Front Physiol | MicroRNA-122-5p Inhibition Improves Inflammation and Oxidative Stress Damage in Dietary-Induced Non-alcoholic Fatty Liver Disease Through Targeting FOXO3. | 2022 | Details |
| A00094 | 35222044 | Front Pharmacol | Antibiotic Disruption of the Gut Microbiota Enhances the Murine Hepatic Dysfunction Associated With a High-Salt Diet. | 2022 | Details |
| A00095 | 35221291 | J Pharmacol Exp Ther | Resveratrol attenuates HFD-induced hepatic lipotoxicity by up-regulating Bmi-1 expression. | 2022 | Details |
| A00096 | 35220997 | Discov Med | Farnesoid X Receptor as a Promising Therapeutic Target for Nonalcoholic Fatty Liver Disease (NAFLD) and the Current Development of Its Agonists. | 2022 | Details |
| A00097 | 35220673 | Liver Int | Knowledge of liver fibrosis stage among adults with NAFLD/NASH improves adherence to lifestyle changes. | 2022 | Details |
| A00099 | 35220605 | Hepatology | Metabolic subtypes of nonalcoholic fatty liver disease patients exhibit distinctive cardiovascular risk profiles. | 2022 | Details |
| A00100 | 35220131 | Phytomedicine | 2,3,5,4'-tetrahydroxy-stilbene-2-O-β-D-glucoside ameliorates NAFLD via attenuating hepatic steatosis through inhibiting mitochondrial dysfunction dependent on SIRT5. | 2022 | Details |
| A00101 | 35219732 | Eur J Pharmacol | mTOR as an eligible molecular target for possible pharmacological treatment of nonalcoholic steatohepatitis. | 2022 | Details |
| A00102 | 35218767 | Life Sci | Hesperidin attenuates hepatic lipid accumulation in mice fed high-fat diet and oleic acid induced HepG2 via AMPK activation. | 2022 | Details |
| A00103 | 35218234 | Hepatology | Dual roles of B lymphocytes in murine models of diet-induced non-alcoholic fatty liver disease. | 2022 | Details |
| A00105 | 35218194 | J Nutr | Clinical Intervention to Reduce Dietary Sugar does not Impact Liver Fat in Latino Youth, Regardless of PNPLA3 Genotype: A Randomized Controlled Trial. | 2022 | Details |
| A00106 | 35217953 | Environ Sci Pollut Res Int | Environmental exposure to low-dose perfluorohexanesulfonate promotes obesity and non-alcoholic fatty liver disease in mice fed a high-fat diet. | 2022 | Details |